<p>Edgestream Partners L.P.在第二季度减持了 PTC Therapeutics, Inc.（纳斯达克股票代码：PTCT - 免费报告）的持股比例，根据该公司最近向美国证券交易委员会提交的 13F 申报文件，持有该生物制药公司股票 22,080 股，较上一季度减持了 31,442 股。Edgestream Partners L.P.在最新报告期结束时持有的 PTC Therapeutics 股份价值 675,000 美元。</p>
<p>获取 <strong>PTC Therapeutics</strong> 警报：</p>
<p>其他几家机构投资者最近也对其持股进行了调整。Choreo LLC 在第二季度将其对 PTC Therapeutics 的持股比例提高了 4.1%。Choreo LLC 现在持有该生物制药公司股票 11,426 股，价值 356,000 美元，较该期间增持了 452 股。亚利桑那州退休系统在第二季度将其对 PTC Therapeutics 的持股比例提高了 3.4%。亚利桑那州退休系统现在持有该生物制药公司股票 19,301 股，价值 590,000 美元，较该期间增持了 636 股。Diversified Trust Co 在第二季度将其对 PTC Therapeutics 的持股比例提高了 5.6%。Diversified Trust Co 现在持有该生物制药公司股票 15,317 股，价值 468,000 美元，较该期间增持了 818 股。ProShare Advisors LLC 在第一季度将其对 PTC Therapeutics 的持股比例提高了 9.3%。ProShare Advisors LLC 现在持有该生物制药公司股票 18,313 股，价值 533,000 美元，较该期间增持了 1,564 股。最后，Allspring Global Investments Holdings LLC 在第一季度购入了 PTC Therapeutics 的新股份，价值约 46,000 美元。</p>
<h2>PTC Therapeutics 股价上涨 1.3%</h2>
<p>PTCT 股票周五开盘价为 36.64 美元。该公司的 50 天移动平均价格为 33.41 美元，200 天移动平均价格为 32.43 美元。该公司的市值为 28.1 亿美元，市盈率为-4.77，贝塔系数为 0.64。PTC Therapeutics, Inc.的 12 个月最低价为 17.53 美元，最高价为 40.69 美元。</p>
<p>PTC Therapeutics（纳斯达克股票代码：PTCT - 获取免费报告）于 8 月 8 日星期四发布了其季度收益报告。该生物制药公司报告的每股收益为（1.16）美元，低于分析师预期的（1.00）美元。该季度公司的营收为 1.867 亿美元，低于分析师预期的 1.9212 亿美元。根据股票分析师的平均预测，预计 PTC Therapeutics, Inc.今年将发布-5.09 美元的每股收益。</p>
<h2>PTC Therapeutics 内部交易</h2>
<p>在其他 PTC Therapeutics 的消息中，首席财务官 Pierre Gravier 于 7 月 16 日星期二以每股 34.02 美元的平均价格出售了公司股票 2,269 股，总价值为 77,191.38 美元。交易完成后，首席财务官在公司持有 53,531 股股票，价值 1,821,124.62 美元。该交易已在向证券交易委员会提交的法律文件中披露，可通过此超链接访问。目前公司 5.50% 的股份由内部持有。</p>
<h2>分析师设定新的价格目标</h2>
<p>许多分析师已对该公司发布了报告。巴克莱将 PTC Therapeutics 的目标股价从 25.00 美元提高至 31.00 美元，并在 8 月 9 日星期五的研究报告中给予该公司 “等权重” 评级。罗伯特·W·贝尔德在 9 月 4 日星期三的研究报告中对 PTC Therapeutics 进行了覆盖。他们给予该股票 “表现优异” 评级，并设定了 44.00 美元的目标股价。坎特菲茨杰拉德在 9 月 17 日星期二的研究报告中重申了 “超重” 评级，并对 PTC Therapeutics 的股票设定了 64.00 美元的目标股价。摩根大通在 6 月 20 日星期四的研究报告中重申了 “超重” 评级，并对 PTC Therapeutics 的股票设定了 53.00 美元的目标股价。最后，高盛集团将 PTC Therapeutics 的目标股价从 18.00 美元上调至 32.00 美元，并在 5 月 28 日星期二的研究报告中给予该股票 “卖出” 评级。三家分析机构给予该股票卖出评级，七家给予持有评级，六家给予买入评级，一家给予强烈买入评级。根据 MarketBeat.com 的数据，PTC Therapeutics 目前的平均评级为 “持有”，并且公司的共识目标股价为 37.64 美元。</p>
<p><strong>查看我们关于 PTCT 的最新报告</strong></p>
<h2>PTC Therapeutics 简介（免费报告）</h2>
<p>PTC Therapeutics, Inc.是一家生物制药公司，专注于在美国和国际市场为患有罕见疾病的患者发现、开发和销售药物。该公司提供 Translarna 和 Emflaza 用于治疗杜兴氏肌营养不良症；Upstaza 用于治疗芳香族 L-氨基酸脱羧酶（AADC）缺乏症，一种中枢神经系统疾病；Tegsedi 和 Waylivra 用于治疗罕见疾病；Evrysdi 用于治疗成人和儿童的脊髓肌萎缩症（SMA）。</p>
<h2>阅读更多</h2>
<ul>
<li>我们喜欢的五只股票胜过 PTC Therapeutics</li>
<li>Russell 2000 指数，投资者如何利用它进行盈利交易</li>
<li>利用 Village Farms 股票，随着大麻市场的发展</li>
<li>什么是股息？购买最佳股息股票</li>
<li>MarketBeat 周评 - 9/16 - 9/20</li>
<li>ESG 股票，投资者应了解的内容</li>
<li>秋季获利不容错过的 3 只零售股</li>
</ul>
<p><strong>想看看其他对 PTCT 持有的对冲基金？</strong> 访问 HoldingsChannel.com 获取 PTC Therapeutics, Inc.（纳斯达克股票代码：PTCT - 免费报告）的最新 13F 申报和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRDVA"/></p>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。在发布之前，这则报道经过了 MarketBeat 编辑团队的审核。请将有关此报道的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 这个能够拯救您退休金的 15 美元&#34;内幕秘密&#34;（来自市场幕后）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx"/></p>
<h2>现在是否值得投资 1000 美元在 PTC Therapeutics？</h2>
<p>在考虑投资 PTC Therapeutics 之前，您可能想要听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票...而 PTC Therapeutics 并不在名单上。</p>
<p>尽管 PTC Therapeutics 目前在分析师中获得&#34;持有&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PTCT

<p>Edgestream Partners L.P.在第二季度将其对 PTC Therapeutics, Inc.的持股比例减少了 58.7%，现持有 22,080 股。其他投资者如 Choreo LLC 和亚利桑那州退休系统也调整了他们的持仓。PTC Therapeutics 股价上涨了 1.3%，达到 0.64 美元，市值为 18.1 亿美元。该公司报告每股亏损 0.16 美元，低于预期。分析师对该股票的评级褒贬不一，平均目标价为 0.64 美元</p>

<p>Edgestream Partners L.P. lessened its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 58.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,080 shares of the biopharmaceutical company's stock after selling 31,442 shares during the quarter. Edgestream Partners L.P.'s holdings in PTC Therapeutics were worth $675,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Edgestream Partners L.P.在第二季度减持了 PTC Therapeutics, Inc.（纳斯达克股票代码：PTCT - 免费报告）的持股比例，根据该公司最近向美国证券交易委员会提交的 13F 申报文件，持有该生物制药公司股票 22,080 股，较上一季度减持了 31,442 股。Edgestream Partners L.P.在最新报告期结束时持有的 PTC Therapeutics 股份价值 675,000 美元。</p>
</div><p>Get <strong>PTC Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>PTC Therapeutics</strong> 警报：</p>
</div><p>Several other institutional investors have also recently made changes to their positions in the company. Choreo LLC raised its position in shares of PTC Therapeutics by 4.1% during the 2nd quarter. Choreo LLC now owns 11,426 shares of the biopharmaceutical company's stock valued at $356,000 after buying an additional 452 shares during the period. Arizona State Retirement System raised its position in PTC Therapeutics by 3.4% in the second quarter. Arizona State Retirement System now owns 19,301 shares of the biopharmaceutical company's stock valued at $590,000 after purchasing an additional 636 shares during the period. Diversified Trust Co raised its position in PTC Therapeutics by 5.6% in the second quarter. Diversified Trust Co now owns 15,317 shares of the biopharmaceutical company's stock valued at $468,000 after purchasing an additional 818 shares during the period. ProShare Advisors LLC raised its position in PTC Therapeutics by 9.3% in the first quarter. ProShare Advisors LLC now owns 18,313 shares of the biopharmaceutical company's stock valued at $533,000 after purchasing an additional 1,564 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new stake in PTC Therapeutics in the first quarter valued at approximately $46,000.</p>
<div class="lb-trans"><p>其他几家机构投资者最近也对其持股进行了调整。Choreo LLC 在第二季度将其对 PTC Therapeutics 的持股比例提高了 4.1%。Choreo LLC 现在持有该生物制药公司股票 11,426 股，价值 356,000 美元，较该期间增持了 452 股。亚利桑那州退休系统在第二季度将其对 PTC Therapeutics 的持股比例提高了 3.4%。亚利桑那州退休系统现在持有该生物制药公司股票 19,301 股，价值 590,000 美元，较该期间增持了 636 股。Diversified Trust Co 在第二季度将其对 PTC Therapeutics 的持股比例提高了 5.6%。Diversified Trust Co 现在持有该生物制药公司股票 15,317 股，价值 468,000 美元，较该期间增持了 818 股。ProShare Advisors LLC 在第一季度将其对 PTC Therapeutics 的持股比例提高了 9.3%。ProShare Advisors LLC 现在持有该生物制药公司股票 18,313 股，价值 533,000 美元，较该期间增持了 1,564 股。最后，Allspring Global Investments Holdings LLC 在第一季度购入了 PTC Therapeutics 的新股份，价值约 46,000 美元。</p>
</div><h2>PTC Therapeutics Trading Up 1.3 %</h2>
<div class="lb-trans"><h2>PTC Therapeutics 股价上涨 1.3%</h2>
</div><p>Shares of PTCT stock opened at $36.64 on Friday. The firm has a fifty day moving average price of $33.41 and a 200 day moving average price of $32.43. The company has a market cap of $2.81 billion, a P/E ratio of -4.77 and a beta of 0.64. PTC Therapeutics, Inc. has a 12 month low of $17.53 and a 12 month high of $40.69.</p>
<div class="lb-trans"><p>PTCT 股票周五开盘价为 36.64 美元。该公司的 50 天移动平均价格为 33.41 美元，200 天移动平均价格为 32.43 美元。该公司的市值为 28.1 亿美元，市盈率为-4.77，贝塔系数为 0.64。PTC Therapeutics, Inc.的 12 个月最低价为 17.53 美元，最高价为 40.69 美元。</p>
</div><p>PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts' consensus estimates of ($1.00) by ($0.16). The company had revenue of $186.70 million for the quarter, compared to analysts' expectations of $192.12 million. On average, equities analysts forecast that PTC Therapeutics, Inc. will post -5.09 EPS for the current year.</p>
<div class="lb-trans"><p>PTC Therapeutics（纳斯达克股票代码：PTCT - 获取免费报告）于 8 月 8 日星期四发布了其季度收益报告。该生物制药公司报告的每股收益为（1.16）美元，低于分析师预期的（1.00）美元。该季度公司的营收为 1.867 亿美元，低于分析师预期的 1.9212 亿美元。根据股票分析师的平均预测，预计 PTC Therapeutics, Inc.今年将发布-5.09 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at PTC Therapeutics</h2>
<div class="lb-trans"><h2>PTC Therapeutics 内部交易</h2>
</div><p>In other PTC Therapeutics news, CFO Pierre Gravier sold 2,269 shares of the company's stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $34.02, for a total value of $77,191.38. Following the completion of the transaction, the chief financial officer now owns 53,531 shares in the company, valued at $1,821,124.62. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. 5.50% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他 PTC Therapeutics 的消息中，首席财务官 Pierre Gravier 于 7 月 16 日星期二以每股 34.02 美元的平均价格出售了公司股票 2,269 股，总价值为 77,191.38 美元。交易完成后，首席财务官在公司持有 53,531 股股票，价值 1,821,124.62 美元。该交易已在向证券交易委员会提交的法律文件中披露，可通过此超链接访问。目前公司 5.50% 的股份由内部持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of analysts have issued reports on the company. Barclays boosted their target price on PTC Therapeutics from $25.00 to $31.00 and gave the company an &#34;equal weight&#34; rating in a research report on Friday, August 9th. Robert W. Baird assumed coverage on PTC Therapeutics in a research report on Wednesday, September 4th. They issued an &#34;outperform&#34; rating and a $44.00 target price on the stock. Cantor Fitzgerald reissued an &#34;overweight&#34; rating and issued a $64.00 target price on shares of PTC Therapeutics in a research report on Tuesday, September 17th. JPMorgan Chase &amp; Co. restated an &#34;overweight&#34; rating and issued a $53.00 price target on shares of PTC Therapeutics in a research note on Thursday, June 20th. Finally, The Goldman Sachs Group boosted their price target on shares of PTC Therapeutics from $18.00 to $32.00 and gave the stock a &#34;sell&#34; rating in a research note on Tuesday, May 28th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, PTC Therapeutics currently has an average rating of &#34;Hold&#34; and a consensus price target of $37.64.</p>
<div class="lb-trans"><p>许多分析师已对该公司发布了报告。巴克莱将 PTC Therapeutics 的目标股价从 25.00 美元提高至 31.00 美元，并在 8 月 9 日星期五的研究报告中给予该公司 “等权重” 评级。罗伯特·W·贝尔德在 9 月 4 日星期三的研究报告中对 PTC Therapeutics 进行了覆盖。他们给予该股票 “表现优异” 评级，并设定了 44.00 美元的目标股价。坎特菲茨杰拉德在 9 月 17 日星期二的研究报告中重申了 “超重” 评级，并对 PTC Therapeutics 的股票设定了 64.00 美元的目标股价。摩根大通在 6 月 20 日星期四的研究报告中重申了 “超重” 评级，并对 PTC Therapeutics 的股票设定了 53.00 美元的目标股价。最后，高盛集团将 PTC Therapeutics 的目标股价从 18.00 美元上调至 32.00 美元，并在 5 月 28 日星期二的研究报告中给予该股票 “卖出” 评级。三家分析机构给予该股票卖出评级，七家给予持有评级，六家给予买入评级，一家给予强烈买入评级。根据 MarketBeat.com 的数据，PTC Therapeutics 目前的平均评级为 “持有”，并且公司的共识目标股价为 37.64 美元。</p>
</div><p><strong>Check Out Our Latest Report on PTCT</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 PTCT 的最新报告</strong></p>
</div><h2>PTC Therapeutics Profile (Free Report)</h2>
<div class="lb-trans"><h2>PTC Therapeutics 简介（免费报告）</h2>
</div><p>PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.</p>
<div class="lb-trans"><p>PTC Therapeutics, Inc.是一家生物制药公司，专注于在美国和国际市场为患有罕见疾病的患者发现、开发和销售药物。该公司提供 Translarna 和 Emflaza 用于治疗杜兴氏肌营养不良症；Upstaza 用于治疗芳香族 L-氨基酸脱羧酶（AADC）缺乏症，一种中枢神经系统疾病；Tegsedi 和 Waylivra 用于治疗罕见疾病；Evrysdi 用于治疗成人和儿童的脊髓肌萎缩症（SMA）。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than PTC Therapeutics</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>Take Advantage of Village Farms Stock as Cannabis Market Evolves</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>MarketBeat Week in Review – 9/16 - 9/20</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>Don’t Miss These 3 Retail Stocks for Fall Gains</li>
</ul>
<div class="lb-trans"><h2>阅读更多</h2>
<ul>
<li>我们喜欢的五只股票胜过 PTC Therapeutics</li>
<li>Russell 2000 指数，投资者如何利用它进行盈利交易</li>
<li>利用 Village Farms 股票，随着大麻市场的发展</li>
<li>什么是股息？购买最佳股息股票</li>
<li>MarketBeat 周评 - 9/16 - 9/20</li>
<li>ESG 股票，投资者应了解的内容</li>
<li>秋季获利不容错过的 3 只零售股</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PTCT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 PTCT 持有的对冲基金？</strong> 访问 HoldingsChannel.com 获取 PTC Therapeutics, Inc.（纳斯达克股票代码：PTCT - 免费报告）的最新 13F 申报和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRDVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PTCT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。在发布之前，这则报道经过了 MarketBeat 编辑团队的审核。请将有关此报道的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ The $15 &#34;Insider Secret&#34; That Could Save Your Retirement (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 这个能够拯救您退休金的 15 美元&#34;内幕秘密&#34;（来自市场幕后）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9451&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in PTC Therapeutics right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1000 美元在 PTC Therapeutics？</h2>
</div><p>Before you consider PTC Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 PTC Therapeutics 之前，您可能想要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PTC Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票...而 PTC Therapeutics 并不在名单上。</p>
</div><p>While PTC Therapeutics currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 PTC Therapeutics 目前在分析师中获得&#34;持有&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Edgestream Partners L.P. 减少了在 PTC Therapeutics, Inc. (NASDAQ:PTCT) 的持股